Clinical Trial Update: Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis [Phase 4]

View source ↗

Summary

Phase 4 trial update comparing SB5 to Humira in adults with moderate to severe plaque psoriasis, focusing on pharmacokinetics, efficacy, safety, and immunogenic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Humira (adalimumab)
• SB5 (adalimumab biosimilar)

Snippet

Sponsor: Samsung Bioepis Co., Ltd. | Conditions: Plaque Psoriasis | Phase 4 | Status: COMPLETED